Pronunciation:
ta-floo-prost
Trade Name(s)
Ther. Class.
ocular hypotensive agent
Pharm. Class.
prostaglandins
Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.
Therapeutic Effect(s):
↓ intraocular pressure.
Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.
Distribution: Unknown.
Metabolism and Excretion: Further metabolized and eliminated.
Half-life: Unknown.
TIME/ACTION PROFILE (↓ in intraocular pressure)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
Ophth | within 2–4 hr | 12 hr | 24 hr |
Contraindicated in:
Use Cautiously in:
EENT: conjunctival hyperemia, blurred vision, cataract, permanent iris pigmentation, eyelid pigmentation, lash pigmentation/increased thickness/↑ number, macular edema, ocular stinging/irritation
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Drug-Drug
Note noted.
Ophth: (Adults): One drop once daily (into conjunctival sac) in the evening into affected eye(s).
Ophthalmic solution : 0.0015% in 0.3 mL single-use containers
Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.
Reduction of intraocular pressure.
To view other topics, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Complete Product Information.